New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison
Gopila Gupta(All India Institute of Medical Sciences), Dennis Dong Hwan Kim(University Health Network), Anežka Kvetková(Masaryk University), Ivana Ježíšková(Masaryk University), Eshrak Al‐Shaibani(University Health Network), Jiřı́ Mayer(Masaryk University), Amirthagowri Ambalavanan(Queen's University), Josephine Anne Lucero, María Agustina Perusini(University Health Network), Daniela Žáčková(Masaryk University), Jessie J.F. Medeiros(Ontario Institute for Cancer Research), May Chiu(University Health Network), Danielle Pyne(University Health Network), Anthea Travas(University Health Network), Tomáš Jurček(Masaryk University), Jaeyoon Kim(LG (United States)), Sagi Abelson(Ontario Institute for Cancer Research)
Cited by 0
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2010|1k
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2007|556